Biumark Dermaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-12-2024
- Paid Up Capital ₹ 0.50 M
as on 02-12-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
as on 02-12-2024
- Revenue 63.41%
(FY 2021)
- Profit 59.01%
(FY 2021)
- Ebitda 104.19%
(FY 2021)
- Net Worth 26.99%
(FY 2021)
- Total Assets -15.72%
(FY 2021)
About Biumark Dermaceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.00 M.
Nandini Jolly and Indu Mehra serve as directors at the Company.
- CIN/LLPIN
U74999DL2018PTC328843
- Company No.
328843
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2018
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Biumark Dermaceuticals Private Limited offer?
Biumark Dermaceuticals Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Eye Cosmetic, Perfume and Fragrances, Body Spray, Salon, Spa Kits & Equipments, Salon Equipment, Common Disease Medicines, Anti Acne Drug, Skin Care Cosmetics, Hair Care Products.
Who are the key members and board of directors at Biumark Dermaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nandini Jolly  | Director | 22-Jan-2018 | Current |
| Indu Mehra | Director | 22-Jan-2018 | Current |
Financial Performance of Biumark Dermaceuticals.
Biumark Dermaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 63.41% increase. The company also saw a substantial improvement in profitability, with a 59.01% increase in profit. The company's net worth Soared by an impressive increase of 26.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biumark Dermaceuticals?
In 2021, Biumark Dermaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Oct 2022 | ₹2.00 M | Open |
How Many Employees Work at Biumark Dermaceuticals?
Unlock and access historical data on people associated with Biumark Dermaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biumark Dermaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biumark Dermaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
